Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Hodgkin lymphoma
Joseph M. Connors, Wendy Cozen, Christian Steidl, et al.
Nature Reviews Disease Primers (2020) Vol. 6, Iss. 1
Closed Access | Times Cited: 157

Showing 1-25 of 157 citing articles:

Managing the TME to improve the efficacy of cancer therapy
Maria Teresa Bilotta, Antonella Antignani, David Fitzgerald
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 134
Recent Advancements in the Application of Circulating Tumor DNA as Biomarkers for Early Detection of Cancers
Mahima Mishra, Rubai Ahmed, Deepak Kumar Das, et al.
ACS Biomaterials Science & Engineering (2024) Vol. 10, Iss. 8, pp. 4740-4756
Open Access | Times Cited: 16
Hematologic cancers in individuals infected by HIV
Antonino Carbone, Emanuela Vaccher, Annunziata Gloghini
Blood (2021) Vol. 139, Iss. 7, pp. 995-1012
Open Access | Times Cited: 76
Clinical applications of gene therapy for rare diseases: A review
Ioannis Papaioannou, James S. Owen, Rafael J. Yáñez‐Muñoz
International Journal of Experimental Pathology (2023) Vol. 104, Iss. 4, pp. 154-176
Open Access | Times Cited: 32
The BTLA–HVEM axis restricts CAR T cell efficacy in cancer
Puneeth Guruprasad, Alberto Carturan, Yunlin Zhang, et al.
Nature Immunology (2024) Vol. 25, Iss. 6, pp. 1020-1032
Closed Access | Times Cited: 14
Crosstalk Between Autophagy and Oxidative Stress in Hematological Malignancies: Mechanisms, Implications, and Therapeutic Potential
Antonio José Cabrera-Serrano, José Manuel Sánchez‐Maldonado, Carmen González‐Olmedo, et al.
Antioxidants (2025) Vol. 14, Iss. 3, pp. 264-264
Open Access | Times Cited: 1
Brentuximab vedotin resistance in classic Hodgkin's lymphoma and its therapeutic strategies: a review
Dayeeta Bera, Dattatreya Roy
Future Journal of Pharmaceutical Sciences (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 7
EBV‐positive B‐cell lymphomas and lymphoproliferative disorders: Review from the perspective of immune escape and immunodeficiency
Akira Satou, Shigeo Nakamura
Cancer Medicine (2021) Vol. 10, Iss. 19, pp. 6777-6785
Open Access | Times Cited: 37
Role of Radiomics-Based Baseline PET/CT Imaging in Lymphoma: Diagnosis, Prognosis, and Response Assessment
Han Jiang, Ang Li, Zhong-You Ji, et al.
Molecular Imaging and Biology (2022) Vol. 24, Iss. 4, pp. 537-549
Closed Access | Times Cited: 24
NFkB Pathway and Hodgkin Lymphoma
Fabrice Jardin
Biomedicines (2022) Vol. 10, Iss. 9, pp. 2153-2153
Open Access | Times Cited: 24
Role of Artificial Intelligence in PET/CT Imaging for Management of Lymphoma
Eren M. Veziroglu, Faraz Farhadi, Navid Hasani, et al.
Seminars in Nuclear Medicine (2023) Vol. 53, Iss. 3, pp. 426-448
Closed Access | Times Cited: 16
The biology of classical Hodgkin lymphoma
Samuel Kosydar, Stephen M. Ansell
Seminars in Hematology (2024) Vol. 61, Iss. 4, pp. 212-220
Closed Access | Times Cited: 5
Evolution in the definition and diagnosis of the Hodgkin lymphomas and related entities
Thomas Tousseyn, Rebecca L. King, Falko Fend, et al.
Virchows Archiv (2022) Vol. 482, Iss. 1, pp. 207-226
Closed Access | Times Cited: 21
Advances in the treatment of Hodgkin lymphoma: Current and future approaches
Fauzia Ullah, Danai Dima, Najiullah Omar, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 12
Tumor microenvironment contribution to checkpoint blockade therapy. Lessons learned from Hodgkin lymphoma
Antonino Carbone, Annunziata Gloghini, Carmelo Carlo‐Stella
Blood (2023)
Open Access | Times Cited: 11
Antibody targeting of surface P‐selectin glycoprotein ligand 1 leads to lymphoma apoptosis and tumorigenesis inhibition
João L. Pereira, Francisca Ferreira, Nuno R. dos Santos
Hematological Oncology (2024) Vol. 42, Iss. 2
Open Access | Times Cited: 4
A first-in-class inhibitor of HSP110 to potentiate XPO1-targeted therapy in primary mediastinal B-cell lymphoma and classical Hodgkin lymphoma
Manon Durand, Vincent Cabaud Gibouin, Laurence Duplomb, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 4
Epigenetic agents plus anti-PD-1 reshapes tumor microenvironment and restores antitumor efficacy in Hodgkin lymphoma
Jing Nie, Chunmeng Wang, Liangtao Zheng, et al.
Blood (2024) Vol. 144, Iss. 18, pp. 1936-1950
Closed Access | Times Cited: 4
In Vitro 3D Models of Haematological Malignancies: Current Trends and the Road Ahead?
Carlotta Mattioda, Claudia Voena, Gianluca Ciardelli, et al.
Cells (2025) Vol. 14, Iss. 1, pp. 38-38
Open Access
Topological importance of CD8+ T-cell enrichment in the tumor microenvironment of classic Hodgkin lymphoma
Hiromichi Takahashi, Shun Ito, Yoko Nakanishi, et al.
Annals of Hematology (2025)
Open Access
Associations Between Immune-Related Conditions and Lymphoid Disorders: An Analysis of the Diverse All of Us Research Program
Hanna Terhaar, Mohammad Saleem, Evan Liu, et al.
Lymphatics (2025) Vol. 3, Iss. 1, pp. 3-3
Open Access
Pediatric Lymphomas: Key Concepts and Clinical Approaches for Pediatricians
Samanta Catueno, Branko Cuglievan
Pediatrics in Review (2025) Vol. 46, Iss. 2, pp. 78-90
Closed Access
Leveraging social media data to study disease and treatment characteristics of Hodgkin’s lymphoma Using Natural Language Processing methods
Zasim Azhar Siddiqui, M. M. Pathan, Sabina O. Nduaguba, et al.
PLOS Digital Health (2025) Vol. 4, Iss. 3, pp. e0000765-e0000765
Open Access
MEPED as salvage therapy for relapsed/refractory Hodgkin’s lymphoma incorporating edited non-oncogene addiction: mTOR as a bottleneck
Dennis Christoph Harrer, Florian Lüke, Tobias Pukrop, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
The immunotherapy real estate of Hodgkin lymphoma
Christian Steidl
Blood (2025) Vol. 145, Iss. 14, pp. 1445-1447
Closed Access
Page 1 - Next Page

Scroll to top